GFAP and glioblastoma: In a study by Müller et al., CTCs were found in the systemic blood circulation in approximately 21% of patients with GBM, as shown by a specific neural biomarker glial fibrillary acidic protein (GFAP), in conjunction with mutations or over-expression of the EGFR gene.